European Journal of Clinical Pharmacology

, Volume 43, Issue 3, pp 265–268 | Cite as

Plasma protein binding of catecholamines, prazosin and propranolol in diabetes mellitus

  • T. S. Trovik
  • R. Jaeger
  • R. Jorde
  • O. Ingebretsen
  • G. Sager
Originals

Summary

In the present study equilibrium dialysis has been used to determine the degree of protein binding of the catecholamines adrenaline and noradrenalin and the adrenergic receptor blockers, prazosin and propranolol in diabetics.

The binding of the catecholamines in plasma from Type I and II diabetic patients was not significantly different from that of healthy subjects. The ratio of the bound and free catecholamine concentrations was correlated with the level of albumin (HSA).

Significantly reduced protein binding of prazosin was observed in Type I and II diabetic subjects compared to healthy volunteers. The binding of propranolol was significantly reduced in Type I patients.

The ratios between the bound and unbound concentrations of prazosin and propranolol were significantly correlated with the levels of a,-acid glycoprotein (AAG). The results suggest that non-enzymatic glycosylation of plasma proteins may increase the unbound fraction of the adrenergic blockers prazosin and propranolol.

Key word

Diabetes mellitus Drug protein binding Catecholamines adrenoceptor blockers prazosin propranolol 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Ruiz-Cabello F, Erill S (1984) Abnormal serum protein bindingof acidic drugs in diabetes mellitus. Clin Pharmacol Ther 36: 691–695PubMedGoogle Scholar
  2. 2.
    Barry MG, Collins WCJ, Feely J (1986) Plasma protein binding of drugs in insulin dependent diabetes mellitus. Br J Pharmaco 189: 719pGoogle Scholar
  3. 3.
    Sager G (1990) Types ofβ-adrenergic binding sites on plasma proteins and blood cells. In: Belpaire F, Bogaert M, Tillement JP, Verbeeck R (eds) Plasma binding of drugs and its consequences. Academia Press, Ghent, pp 43–53Google Scholar
  4. 4.
    Rubin P, Blaschke T (1980) Prazosin protein binding in health and disease. Br J Clin Pharmacol 9: 177–182PubMedGoogle Scholar
  5. 5.
    Dale O, Nilsen OG (1984) Differences in the serum protein binding of prazosin in man and rat. Biochem Pharmacol 33: 1719–1724CrossRefPubMedGoogle Scholar
  6. 6.
    Brunner F, Muller WE (1985) Prazosin binding to human α1-acid glycoprotein (orosomucoid), human serum albumin, and human serum. Further characterization of the „single drug binding site” of orosomucoid. J Pharm Pharmacol 37: 305–309PubMedGoogle Scholar
  7. 7.
    Sager G, Jæger R, Little C (1989) Binding of prazosin to α1-acid glycoprotein and albumin: effect of protein purity and concentrations. Pharmacol Toxicol 64: 365–368PubMedGoogle Scholar
  8. 8.
    Sager G, Bratlid H, Little C (1987) Binding of catecholamines to alpha-1 acid glycoprotein, albumin, and lipoproteins in human serum. Biochem Pharmacol 36: 3607–3612CrossRefPubMedGoogle Scholar
  9. 9.
    Sager G, Slørdal L, Huseby NE, Florholmen J (1991)β-Adrenoceptor regulation in insulin-dependent diabetes mellitus. Scand J Clin Lab Invest 51: 283–288PubMedGoogle Scholar
  10. 10.
    Hoeldtke RD, Boden G, Shuman CR, Owen OE (1982) Reduced epinephrine secretion and hypoglycemia unawareness in diabetic autonomic neuropathy. Ann Intern Med 96: 459–462PubMedGoogle Scholar
  11. 11.
    Berlin I, Grimaldi A, Bosquet F, Puech AJ (1986) Decreased, adrenergic sensitivity in insulin-dependent diabetic subjects. J Clin Endocrin Metab 63: 262–265Google Scholar
  12. 12.
    Berlin I, Grimaldi A, Landault C, Zoghbi F, Thervet F, Puech AJ, Legrand JC (1988) Lack of hypoglycemic symptoms and decreasedβ-adrenergic sensitivity in insulin-dependent patients. J Clin Endocrin Metab 66: 273–278Google Scholar
  13. 13.
    McMillan DE (1989) Increased levels of acute-phase serum proteins in diabetes. Metabolism 38: 1042–1046CrossRefPubMedGoogle Scholar
  14. 14.
    Sager G, Hansteen V, Aakesson I, Jacobsen S (1981) Effect of heparin on serum binding of propranolol in the acute phase of myocardial infarction. Br J Clin Pharmacol 12: 613–620PubMedGoogle Scholar
  15. 15.
    Kremer JMH, Wilting J, Janssen LHM (1988) Drug binding to human alpha-1-acid glycoprotein in health and disease. Pharmacol Rev 40: 1–47PubMedGoogle Scholar
  16. 16.
    Sager G, Trovik TS, Slørdal L, Jæger R, Prytz P, Brox J, Reiker⫗s O (1988) Catecholamine binding and concentrations in the acute phase plasma after surgery. Scand J Clin Lab Invest 48: 419–424PubMedGoogle Scholar
  17. 17.
    Ziegler MG, Lake CR, Kopin IJ (1976) Plasma noradrenaline increases with age. Nature 261: 333–335CrossRefPubMedGoogle Scholar
  18. 18.
    Lake CR, Ziegler MG, Coleman MD, Kopin IJ (1977) Ageadjusted plasma norepinephrine levels are similar in normotensive and hypertensive subjects. N Engl J Med 296: 208–209PubMedGoogle Scholar

Copyright information

© Springer-Verlag 1992 1992

Authors and Affiliations

  • T. S. Trovik
    • 1
  • R. Jaeger
    • 1
  • R. Jorde
    • 2
  • O. Ingebretsen
    • 3
  • G. Sager
    • 1
  1. 1.Department of Pharmacology Institute of Medical BiologyUniversity of TromsøTromsøNorway
  2. 2.Department of Internal MedicineInstitute of Clinical MedicineNorway
  3. 3.Department of Clinical Chemistry, Institute of Medical BiologyUniversity of TromsøNorway

Personalised recommendations